Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;33(5):771-782.
doi: 10.1002/mds.27361. Epub 2018 Mar 23.

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

Tanya Simuni  1 , Andrew Siderowf  2 , Shirley Lasch  3 , Chris S Coffey  4 , Chelsea Caspell-Garcia  4 , Danna Jennings  5 , Caroline M Tanner  6 , John Q Trojanowski  2 , Leslie M Shaw  2 , John Seibyl  3 , Norbert Schuff  6 , Andrew Singleton  7 , Karl Kieburtz  8 , Arthur W Toga  9 , Brit Mollenhauer  10 , Doug Galasko  11 , Lana M Chahine  2 , Daniel Weintraub  2 , Tatiana Foroud  12 , Duygu Tosun  6 , Kathleen Poston  13 , Vanessa Arnedo  14 , Mark Frasier  14 , Todd Sherer  14 , Sohini Chowdhury  14 , Kenneth Marek  3 ; Parkinson's Progression Marker Initiative*
Affiliations

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

Tanya Simuni et al. Mov Disord. 2018 May.

Abstract

Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes in early, untreated PD.

Methods: We describe 5-year longitudinal change of the MDS-UPDRS and other clinical measures using results from the Parkinson's Progression Markers Initiative, a longitudinal cohort study of early Parkinson's disease (PD) participants untreated at baseline. We also provide data on the longitudinal change in dopamine transporter 123-I Ioflupane striatal binding and correlation between the 2 measures.

Results: A total of 423 PD participants were recruited, and 358 remain in the study at year 5. Baseline MDS-UPDRS total score was 32.4 (standard deviation 13.1), and the average annual change (assessed medications OFF for the treated participants) was 7.45 (11.6), 3.11 (11.7), 4(11.9), 4.7 (11.1), and 1.74(11.9) for years 1, 2, 3, 4, and 5, respectively (P < .0001 for the change over time), with a steeper change in year 1. Dopaminergic therapy had a significant effect on the change of MDS-UPDRS. There was a significant longitudinal change in dopamine transporter binding in all striatal regions (P < .001). There was a significant but weak correlation between MDS-UPDRS and dopamine transporter binding at baseline and years 1, 2, and 4, but no correlation between the rate of change of the 2 variables.

Conclusions: We present 5-year longitudinal data on the change of the MDS-UPDRS and other clinical and dopamine transporter imaging outcome measures in early PD. These data can be used for sample size estimates for interventional studies in the de novo PD population. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; disease subtypes; gait disorder predominant; postural instability; tremor dominant.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) MDS‐UPDRS Total Score over time in all PD subjects. (b) MDS‐UPDRS Total Score over time in PD subjects by treatment group. (c) Kaplan‐Meier curve for time to start PD medications in PD subjects. (d) DaTSCAN over time in PD subjects.
See this image and copyright information in PMC

References

    1. Fahn SER, Members of the UPDRS Development Committee . The Unified Parkinson's Disease Rating Scale In: Fahn S. Marsden CD, Calne DB, Goldstein M, ed. Recent developments in Parkinson's disease. Vol 2 Florham Park, NJ: Macmillan Health Care Information; 1987;153‐164.
    1. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence‐based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58(1):11‐17. - PubMed
    1. Elm JJ, Goetz CG, Ravina B, et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol 2005;57(2):197‐203. - PubMed
    1. Goetz CG, Fahn S, Martinez‐Martin P, et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007;22(1):41‐47. - PubMed
    1. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129‐2170. - PubMed

Publication types